1. Home
  2. PROV vs BMEA Comparison

PROV vs BMEA Comparison

Compare PROV & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Provident Financial Holdings Inc.

PROV

Provident Financial Holdings Inc.

N/A

Current Price

$15.38

Market Cap

98.1M

Sector

Finance

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.19

Market Cap

96.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PROV
BMEA
Founded
1956
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.1M
96.9M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
PROV
BMEA
Price
$15.38
$1.19
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$16.25
$8.71
AVG Volume (30 Days)
5.9K
1.2M
Earning Date
10-28-2025
11-04-2025
Dividend Yield
3.65%
N/A
EPS Growth
N/A
N/A
EPS
0.90
N/A
Revenue
$39,823,000.00
N/A
Revenue This Year
$4.14
N/A
Revenue Next Year
$3.70
N/A
P/E Ratio
$17.06
N/A
Revenue Growth
0.07
N/A
52 Week Low
$12.98
$0.87
52 Week High
$16.70
$7.06

Technical Indicators

Market Signals
Indicator
PROV
BMEA
Relative Strength Index (RSI) 47.02 48.12
Support Level $15.01 $0.95
Resistance Level $15.65 $1.12
Average True Range (ATR) 0.41 0.11
MACD 0.03 0.03
Stochastic Oscillator 34.07 53.24

Price Performance

Historical Comparison
PROV
BMEA

About PROV Provident Financial Holdings Inc.

Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: